T-Cure Bioscience

820 TCR Clin0 multiple cancers; 806 TCR Clin0 solid tumors; 402 TCR RD/Clin0 solid tumors; 821 TCR RD/Clin0 solid tumors; 830 TCR RD/Clin0 solid tumors; therapeutic vaccine RD/Clin0 multiple cancers

T-Cure Bioscience is pioneering T cell receptor (TCR) therapy to find effective and durable cures for human cancers. T cell engineering involves genetically modifying the immune cells to redirect them toward tumors. T-Cure is identifying and isolating high avidity TCRs which specifically recognize intracellular or cell-surface targets in solid tumors. These TCRs can then be introduced into viral vectors and inserted in a patients’ own T cells in an ex vivo setting. T-Cure’s lead program, 800TCR, targets HERV-E, a protein that gets turned on during tumor development. Currently, the program is in clinical stages for patients with renal cell carcinoma.

Jobs: